197 related articles for article (PubMed ID: 31407320)
1. The impact of SOCS1 mutations in diffuse large B-cell lymphoma.
Mellert K; Martin M; Lennerz JK; Lüdeke M; Staiger AM; Kreuz M; Löffler M; Schmitz N; Trümper L; Feller AC; Hartmann S; Hansmann ML; Klapper W; Stein H; Rosenwald A; Ott G; Ziepert M; Möller P
Br J Haematol; 2019 Dec; 187(5):627-637. PubMed ID: 31407320
[TBL] [Abstract][Full Text] [Related]
2. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
3. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Xu-Monette ZY; Wu L; Visco C; Tai YC; Tzankov A; Liu WM; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Kahl BS; Winter JN; Xu W; Li J; Go RS; Li Y; Piris MA; Møller MB; Miranda RN; Abruzzo LV; Medeiros LJ; Young KH
Blood; 2012 Nov; 120(19):3986-96. PubMed ID: 22955915
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
5. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
6. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
[TBL] [Abstract][Full Text] [Related]
8. SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients.
Schif B; Lennerz JK; Kohler CW; Bentink S; Kreuz M; Melzner I; Ritz O; Trümper L; Loeffler M; Spang R; Möller P
Oncotarget; 2013 Jan; 4(1):35-47. PubMed ID: 23296022
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP.
Liu D; Wang Y; Dong M; Guan S; Wang Y; Sun H; Wu N; Li S; Bai J; Chen F; Sun D; Jin Y
Ann Hematol; 2017 Feb; 96(2):227-235. PubMed ID: 27822610
[TBL] [Abstract][Full Text] [Related]
10. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
11. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
12. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.
Lisenko K; Dingeldein G; Cremer M; Kriegsmann M; Ho AD; Rieger M; Witzens-Harig M
BMC Cancer; 2017 May; 17(1):359. PubMed ID: 28532396
[TBL] [Abstract][Full Text] [Related]
13. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
15. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
Seki R; Ohshima K; Fujisaki T; Uike N; Kawano F; Gondo H; Makino S; Eto T; Moriuchi Y; Taguchi F; Kamimura T; Tsuda H; Ogawa R; Shimoda K; Yamashita K; Suzuki K; Suzushima H; Tsukazaki K; Higuchi M; Utsunomiya A; Iwahashi M; Imamura Y; Tamura K; Suzumiya J; Yoshida M; Abe Y; Matsumoto T; Okamura T
Cancer Sci; 2009 Oct; 100(10):1842-7. PubMed ID: 19656156
[TBL] [Abstract][Full Text] [Related]
17. 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis.
Araie H; Sakamaki I; Matsuda Y; Tai K; Ikegaya S; Itoh K; Kishi S; Oiwa K; Okura M; Tasaki T; Hosono N; Ueda T; Yamauchi T
Intern Med; 2017 Sep; 56(18):2407-2413. PubMed ID: 28824057
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
19. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
[TBL] [Abstract][Full Text] [Related]
20. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]